Dietary Supplements: Nobel Science or Misleading Marketing? Inside the Controversy Behind Elysium's "Basis"

Table of Contents

• Key Points
• The $20 Billion Supplement Industry
• How Supplements Are Regulated (and Why It Matters)
• The Science of Aging: Real Promise or Distant Dream?
• Inside Elysium: The Story of "Basis"
• The Nobel Laureate Connection
• What the "Clinical Trial" Actually Showed
• Two Conflicting Views of Elysium
• What This Means for Patients
• Limitations of This Analysis
• Recommendations for Supplement Users
• Frequently Asked Questions
• Source Information

Key Points

• Most dietary supplements have little or no scientific evidence for their claimed health benefits, despite $20 billion in annual US sales.
• Unlike prescription drugs, supplements can be sold without prior FDA approval and often lack proof of effectiveness or safety.
• Elysium's Basis contains nicotinamide riboside and pterostilbene, which have shown benefits in cells and animals but not proven benefits in humans.
• An unpublished study showed Basis increased NAD levels, but that does not prove improved cellular health or any health outcome.
• Patients should look for clinical trial evidence, be skeptical of celebrity endorsements, and talk to their doctor before taking supplements.

The $20 Billion Supplement Industry

Millions of Americans seeking improved health take "natural product" dietary supplements—everything from Gobi berries to Echinacea. The supplement industry sells vitamins, minerals, herbs, botanicals, and a growing list of other "natural" substances, bringing in more than $20 billion in annual US revenue. That's a staggering amount of money flowing through an industry with remarkably loose oversight.

Yet here's the uncomfortable truth: most of these products have little or no scientific evidence that they actually confer health benefits. This disconnect has created ongoing struggles between the supplement industry and the medical science community—struggles that are hardly surprising given what's at stake financially and for public health.

So when seven Nobel laureates attached their names to a company marketing an unproven dietary supplement, eyebrows were raised across the scientific community. This was especially notable at a time when the integrity and reproducibility of bioscience research was already being questioned. The product in question was marketed as an "anti-aging" supplement that improves "cellular health" (though a correction to the original article clarified that Elysium itself does not use the phrase "anti-aging" in its marketing materials for Basis). This description connects it to a long lineage of "cures," remedies, and "miracle drugs" that extend back at least as far as the myth of the Fountain of Youth.

How Supplements Are Regulated (and Why It Matters)

The regulatory path for bringing a supplement to market differs dramatically from that of prescription drugs. Prescription drugs must undergo rigorous testing through clinical trials and receive approval from the FDA before they can be sold. Supplements face no such requirement.

Here's the key distinction that every patient should understand:

• Supplements cannot legally claim to treat, cure, or prevent specific diseases
• Supplements can claim, without any evidence, to affect the "structure and function" of the body
• Many supplements claim to extend life and improve various symptoms, but industry standards are inconsistent and widely criticized
• Products may not actually contain the labeled substances in the specified amounts
• Some supplements contain harmful contaminants

The regulatory and legal system currently in place isn't up to the task of addressing these issues. This means patients are essentially being asked to trust manufacturers at their word, with no guarantee that what's on the label matches what's in the bottle—or that the product does anything beneficial at all.

The Science of Aging: Real Promise or Distant Dream?

It's important to note that the science of aging is genuinely exciting. Researchers have found that manipulating specific genes in yeast, worms, and mice can increase their lifespan. These are real, reproducible findings in legitimate laboratories.

Here's the promising part: the same genes exist in humans. This means that, theoretically, manipulating these genes could lead to treatments for human age-related diseases, and potentially for aging itself. This is not fringe science—it's at the cutting edge of contemporary biomedical research.

But here's the catch that often gets lost in the marketing: translating such insights from the laboratory to the clinic is challenging. Despite decades of promising research, no therapies based on these ideas have emerged. The gap between "this works in a worm" and "this works in a human patient" is enormous, and it's a gap that supplement marketing often glosses over entirely.

Inside Elysium: The Story of "Basis"

Enter Elysium Health. Backed by top-tier venture capital, the company crafted a business opportunity in the supplement world. Their strategy was clever: they identified two marketed "natural molecules" with plausible but unproven benefit, combined them into a new pill, packaged it attractively, and named it Basis.

The two ingredients in Basis are:

1. Nicotinamide riboside — a version of vitamin B3
2. Pterostilbene — an antioxidant found in blueberries

Both ingredients have produced benefits in cells and animals in laboratory studies, and both are generally viewed as safe for human consumption. But benefit in a petri dish or a mouse is a far cry from proven benefit in a human body.

To differentiate themselves from other supplement providers, Elysium engaged a highly regarded researcher—MIT's Leonard Guarente—as scientific founder and the public face of the company. Guarente made important discoveries about aging in yeast. He had been frustrated by unsuccessful efforts to develop anti-aging drugs through the FDA approval process, so he sought another path. Along with Elysium, he recruited seven Nobel laureates to advise the company and lend their names to its efforts.

With Nobelists on board, additional outstanding scientists became advisors as well. Using sophisticated advertising and social media, the company sells Basis directly to consumers, promoting vague health benefits linked to the glow of scientific stars.

The Nobel Laureate Connection

The use of Nobel Prize winners as advisors is unusual in the supplement world, and it raises uncomfortable questions. In 2015, the Boston Globe reported on Elysium's launch in a story featuring two Nobelists from Harvard. At the time, Jeffrey Flier was the dean of Harvard Medical School, and he received expressions of concern from faculty members who saw financial incentives driving an otherwise inexplicable association. Flier initially thought that explanation unlikely, but he was genuinely puzzled by the arrangement.

Flier contacted one of the Nobel laureates directly: Eric Kandel, professor of neuroscience at Columbia and chair of Elysium's scientific advisory board. Kandel won the Nobel Prize in 2000 for fundamental discoveries about the cellular basis of memory, and he remains active and vital at age 87.

When asked about his association with Elysium, Kandel cited the importance of new approaches to aging and defended the plausibility of the science. He lauded the company's commitment to clinical trials—a rare feature among supplement companies. However, when reminded that people were being treated without such trials, he admitted unhappiness about this and said he hoped the practice would change. He was also uncomfortable that Nobel prizes were being used as a marketing strategy.

Five other advisors praised Elysium's strategy for developing safe and effective natural products. They stressed the importance of clinical trials, but they weren't clear about how these trials would be conducted or how the results would be used. Here's perhaps the most telling detail: none of them recommended that people take Basis.

What the "Clinical Trial" Actually Showed

Elysium does promote one feature that's unique among supplement companies: an intention to perform clinical trials. But a closer look at what they've actually produced is revealing.

An unpublished study promoted on their website claims that Basis increases levels of a key molecule called NAD (nicotinamide adenine dinucleotide), which plays a role in cellular energy and metabolism. While potentially of scientific interest, this "trial" provides no evidence that Basis improves "cellular health" — which is, after all, the stated goal of taking the supplement.

Measuring one molecule in the blood does not prove that a product makes cells healthier, slows aging, or improves any health outcome. The history of drug development is filled with examples where promising results in animals and cells failed to translate into actual health benefits in humans.

Two Conflicting Views of Elysium

Flier presents two conflicting narratives to describe the company. Understanding these two perspectives is essential for any patient considering whether to take a supplement like Basis.

Narrative One: The Skeptical View. In this version, Elysium sells supplements in a lightly regulated and evidence-free environment. The company leverages the reputations of great scientists to add credibility to its marketing. It overstates the narrative about clinical trials to sell products, with sales having primacy over health efficacy.

Narrative Two: The Reformist View. In this version, Elysium is genuinely reforming the supplement industry by engaging great scientists and rigorously testing products to establish or refute health benefits. The clinical trials are real, and the company's intentions are honorable.

Which narrative more closely resembles reality? Flier argues that the answer depends on what the scientific advisors do next. They could use their clout to promote the second version by insisting that their Nobel credentials not be employed as marketing tools, and by demanding that Basis—and any future products—be shown to have real efficacy before being marketed, even if not legally required.

What This Means for Patients

For patients, this story carries several important lessons. First, a prestigious name on a product does not equal scientific proof. The Nobel laureates associated with Elysium are brilliant scientists, but even their own advisors didn't recommend that people take the product.

Second, the ingredients in Basis might improve health—they deserve careful study. But the history of drug development reveals that despite hopeful results in animals and cells, and despite the good intentions of Elysium's advisors, it's unlikely that Basis improves health in the ways its marketing suggests.

Third, the supplement industry operates with far less oversight than the prescription drug industry. The regulatory and legal system isn't equipped to ensure supplements contain what they claim or do what they promise. Patients should understand that buying a supplement is fundamentally different from taking a FDA-approved medication—you're accepting a much higher level of uncertainty about both safety and effectiveness.

Finally, this controversy has implications beyond one product. If the supplement industry could more closely mirror properly documented medical research, the nation's health might genuinely be enhanced. The scientific advisors at Elysium have the opportunity to model what that could look like—by insisting that products be proven effective before being marketed, even when not legally required.

Limitations of This Analysis

This article is an opinion piece by Dr. Jeffrey S. Flier, distinguished service professor at Harvard Medical School and former dean of the school. It is not a peer-reviewed scientific study, and it does not present new clinical trial data. The analysis is based on Flier's expertise, his review of Elysium's practices, and his interviews with advisors, including Eric Kandel.

Flier's description of Elysium is based on publicly available information and his conversations with company advisors. The unpublished study mentioned in the article was not independently verified. It's also worth noting that a correction was issued to the original article: Elysium does not use the phrase "anti-aging" in its marketing materials for Basis, though the supplement is widely understood to be positioned as an anti-aging product.

Additionally, this piece does not evaluate whether any individual supplement—including Basis—is harmful or beneficial. It focuses specifically on the marketing practices and scientific evidence (or lack thereof) behind one product.

Recommendations for Supplement Users

Based on the issues raised in this article, here are practical steps patients can take when considering any dietary supplement:

1. Look for clinical trial evidence, not just laboratory studies. Results in cells or animals do not predict benefits in humans. Ask whether the product has been tested in randomized, controlled human trials published in reputable medical journals.
2. Be skeptical of celebrity endorsements—including scientist celebrity endorsements. A Nobel Prize validates past scientific achievements, not the effectiveness of a commercial product.
3. Check whether the product has been independently tested. Third-party testing organizations can verify that a supplement contains what its label claims, though they cannot verify health benefits.
4. Talk to your doctor before taking supplements. Some supplements can interact with prescription medications or cause harm in certain medical conditions.
5. Ask what the clinical trials actually measured. A supplement company may point to a study showing changes in a blood marker, but that doesn't mean the product improves health outcomes like longevity, disease prevention, or quality of life.
6. Be wary of vague health claims. Terms like "cellular health," "vitality," and "support" are often used to suggest benefits without making specific, testable claims.

The bottom line: the dietary supplement industry is a $20 billion business operating with minimal regulation and, frequently, minimal scientific evidence. The involvement of respected scientists in companies like Elysium is a double-edged sword—it could lead to much-needed reform, or it could simply lend an air of legitimacy to unproven products. For now, patients should approach all supplements, regardless of marketing, with informed skepticism and honest conversations with their healthcare providers.

Frequently Asked Questions

Why did Nobel laureates associate with Elysium Health's supplement Basis?

Seven Nobel laureates joined Elysium's advisory board. One, Eric Kandel, said he supported new approaches to aging and praised the company's commitment to clinical trials. However, he was uncomfortable that Nobel prizes were used as marketing and did not recommend that people take Basis. Other advisors stressed clinical trials but were unclear on how results would be used.

What did the clinical trial for Basis actually show?

An unpublished study promoted on Elysium's website showed that Basis increased levels of NAD, a molecule involved in cellular energy. But this did not prove that the supplement improves cellular health, slows aging, or improves any health outcome. Measuring one molecule in the blood is not evidence of real health benefits.

Is there real science behind anti-aging treatments?

Yes, research in yeast, worms, and mice has shown that manipulating certain genes can increase lifespan, and these genes exist in humans. However, translating these findings to human treatments is very challenging, and despite decades of research, no therapies based on these ideas have emerged. The gap between animal studies and human benefits is enormous.

What are the ingredients in Elysium's Basis supplement?

Basis contains two ingredients: nicotinamide riboside, a version of vitamin B3, and pterostilbene, an antioxidant found in blueberries. Both have shown benefits in cells and animals in laboratory studies and are generally viewed as safe for human consumption, but neither has proven benefit in humans.

What should patients consider before taking a dietary supplement?

Look for evidence from randomized, controlled human trials published in reputable journals, not just lab studies. Be skeptical of endorsements, including from scientists, because a Nobel Prize does not validate a product. Check if the product was independently tested, ask your doctor about interactions, and be wary of vague claims like 'cellular health' or 'vitality'.

Did Elysium's scientific advisors recommend taking Basis?

No. None of the advisors interviewed recommended that people take Basis. While they praised Elysium's strategy and stressed the importance of clinical trials, they did not endorse the product for personal use. This suggests that even the scientists involved did not see enough evidence to recommend it to patients.

Should I get a second opinion before taking a dietary supplement like Basis?

Before taking any dietary supplement marketed with vague health claims such as 'cellular health' or 'vitality,' a second opinion is worth seeking. The supplement industry operates with minimal regulation, and products are not required to prove they work. A prestigious scientist's name does not equal proof; even the Nobel advisors associated with Elysium's Basis did not recommend taking it. A second opinion can help clarify whether a product has randomized controlled human trial evidence, whether claims are specific, and whether it is safe alongside your current medications. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Dietary supplements Nobel or ignoble - The Boston Globe

Note: This patient-friendly article is based on peer-reviewed research and expert commentary originally published in The Boston Globe. The original article included a correction noting that Elysium does not use the phrase "anti-aging" in its marketing materials for Basis.